Spruce Biosciences, Inc. (SPRB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates - ...

Spruce Biosciences, Inc. (SPRB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

As of January 20, 2024, the average one-year price target for Spruce Biosciences is 8.50. The forecasts range from a low of 7.07 to a high of $10.50. The average price target represents an increase of ...

The average one-year price target for Spruce Biosciences (NasdaqCM:SPRB) has been revised to $137.19 / share. This is an increase of 2,045.14% from the prior estimate of $6.40 dated November 7, 2025.

Hong Kong-based Harbour BioMed on Sunday exercised its warrant to acquire the common stock in Spruce Biosciences Inc. (NASDAQ: SPRB). Following this transaction, Harbour BioMed holds approximately 3.8 ...

Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the most promising micro-cap stocks according to analysts. On February 18, Spruce Biosciences recently concluded successful Type B meetings with the FDA ...

Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s ...

) has been revised to $213.69 / share. This is an increase of 55.76% from the prior estimate of $137.19 dated November 14, 2025. The price target is an average of many targets provided by analysts.